Concomitant chemoradiotherapy followed by adjuvant chemotherapy in parotid gland undifferentiated carcinoma

M. Airoldi, A. M. Gabriele, P. Gabriele, F. Pedani, S. Marchionatti, G. Succo, F. Beatrice, C. Bumma

Research output: Contribution to journalArticlepeer-review

Abstract

Aims and background: Undifferentiated carcinoma of the parotid gland is a poor-prognosis lesion. Results in unresectable lesions, treated with radiotherapy alone, are very disappointing. Methods: Six patients with T3-4 N0-1 inoperable lesions were treated with conventional radiotherapy (64-70 Gy, 2 Gy per fraction 5 times a week) and concomitant cisplatin (100 mg/m2, days 1, 22 and 43). Four weeks after radiotherapy, adjuvant chemotherapy (cisplatin, 80 mg/m2, day 1, + VP16, 100 mg/m2, days 1, 3 and 5, q = 3 weeks, for 3 cycles) was given. Results: A median dose of 66 Gy (range, 64-70 Gy) was delivered, and all patients received 3 courses of cisplatin during radiotherapy. Five of 6 patients received all three chemotherapeutic adjuvant courses. Two months after the end of treatment, 3 CR (50%), 2 PR (33%) and 1 NC (16%) was observed. Median CR and PR duration was 26+ and 10 months, respectively. Median overall survival was 18 months. No severe acute or late toxicity was observed. Conclusions: Concomitant chemoradiotherapy followed by adjuvant chemotherapy in advanced unresectable undifferentiated parotid carcinoma is feasibile and well tolerated. The high percentage of long-lasting CR is encouraging.

Original languageEnglish
Pages (from-to)14-17
Number of pages4
JournalTumori
Volume87
Issue number1
Publication statusPublished - 2001

Keywords

  • Chemotherapy
  • Parotid gland
  • Radiation therapy
  • Salivary gland tumor

ASJC Scopus subject areas

  • Cancer Research

Fingerprint Dive into the research topics of 'Concomitant chemoradiotherapy followed by adjuvant chemotherapy in parotid gland undifferentiated carcinoma'. Together they form a unique fingerprint.

Cite this